The Valuation Analyst

📊 Fundamental & Technical Analyst
🧠 I help investors cut through noise → better decisions
⚠️ Not financial advice

[The Valuation Analyst @ValuationEdge_]

Most investors buy stories, not businesses.

I started @valuationedge_ to do the opposite — to cut through noise and find mispriced growth using fundamentals.

I share:
• Deep dives on real businesses
• Data-backed setups that make sense
• Simple frameworks that help you invest with conviction

No hype. No fluff. Just fundamentals.
Follow if you want logic to beat noise.

[The Valuation Analyst @ValuationEdge_]

@vispen123 Anytime 😀

[The Valuation Analyst @ValuationEdge_]

$FLNC might be one of the most overlooked AI infrastructure plays.

AI data centers are about to explode in power demand…
Which means we’ll need way more renewable energy + storage to keep them running.
That’s exactly where Fluence steps in.

Revenue growth:
2019 → 2025E
$92M → $2.7B 🤯
Management guiding ~$2.6B this year.
Operating profits turning positive for the first time.

[The Valuation Analyst @ValuationEdge_]

@AleeIrurzun Check back in a year or two

[The Valuation Analyst @ValuationEdge_]

$TDMX revenue up 1,348% since 2022

$TMDX operating income turning positive

What more do we need to say?

$TMDX risk/reward looks great even at 50x earnings

[The Valuation Analyst @ValuationEdge_]

@commonsenseplay $SE?

[The Valuation Analyst @ValuationEdge_]

@investingluc Appreciate you!

[The Valuation Analyst @ValuationEdge_]

@hamptonism Creatine, vitamin D, caffeine

[The Valuation Analyst @ValuationEdge_]

@TheLongInvest What are the most expensive supplements/peptides specifically for you?

Respect it but 25k is insane, would love to know the whole stack/routine

[The Valuation Analyst @ValuationEdge_]

@TheLongInvest $AMZN

[The Valuation Analyst @ValuationEdge_]

@ZetaGlobal @dsteinberg10000 Wow, that’s all I have to say @dsteinberg10000

[The Valuation Analyst @ValuationEdge_]

$ZETA posting another 💣 quarter

18th straight beat and raise

Nobody else in the market is doing this

Guiding 40% rev increase for Q1’26

$ZETA is a no brainer around 3x sales

[Zeta @ZetaGlobal]

4Q was a record quarter to cap a record year 📈

✔��� Our 18th straight “beat and raise”
✔️ $395M revenue, an increase of 25% Y/Y (28% growth when excluding revenue from political candidates, LiveIntent and Marigold's Enterprise Business)
✔️ Highest-ever adj. EBITDA and FCF margins
✔️ Positive GAAP net income
✔️ Above the “rule of 50” again, and more

With our proprietary data that improves with every customer interaction, intelligence that sharpens with every decision, and Athena by Zeta™ expected to become the interface that lowers the barriers to enterprise-wide adoption, we are positioned to be the AI disruptor in enterprise marketing software.

Shoutout to our incredible Team Zeta for driving another quarter of growth!

Learn more about our 4Q and full-year 2025 earnings results: https://t.co/SFDQAPYfIc

[The Valuation Analyst @ValuationEdge_]

@oguzerkan Do I sell all $PYPL and put it into $PGY?

[The Valuation Analyst @ValuationEdge_]

@oguzerkan Do I sell all $PYPL and put it into $PGY?

[The Valuation Analyst @ValuationEdge_]

@mvcinvesting $UNH

[The Valuation Analyst @ValuationEdge_]

@StockChaser_ Love this, simple rules

Don’t need fancy charts or tech to do it either. Simple reading, studying, and applying knowledge

Emotions are 90% of the difficulty in markets

[The Valuation Analyst @ValuationEdge_]

@grok @TheLongInvest @grok What is the argument for peptide usage to be more normal for biological diseases/conditions that typical physicians can’t treat well?

Will we start to rely on AI to diagnose/solve our health issues more than doctors because of cost effectiveness?

[The Valuation Analyst @ValuationEdge_]

@SahilBloom Applying yourself, reading

[The Valuation Analyst @ValuationEdge_]

@adamkhootrader @grok why does selling and moving money around in the market feel productive when often times letting compounders grow is the best move?

[The Valuation Analyst @ValuationEdge_]

$OSCR growth speaks for itself

EV currently: $1.7B

2026 Revenue Guidance: $18B

Puts $OSCR at .1x EV/Sales based on guidance

Cheap is an understatement

$OSCR path to profitability could make this easily $30+ in the next year

$OSCR is an asymmetric bet at $13

[The Valuation Analyst @ValuationEdge_]

Right with you here @Ashton_1nvests

$UNH and $OSCR look like boring plays compared to AI names

It’s not exciting

It’s consistent cash flow and demand however

Everyone needs healthcare

$UNH and $OSCR are both trading at very reasonable prices

Not saying put all your money in healthcare but for stability/margin of safety, both are great value

[Ashton Invests @Ashton_1nvests]

I wouldn’t be surprised at all if healthcare ends up leading in 2026.

While everyone has been focused on AI and mega-cap tech, healthcare has quietly been resetting. Valuations have compressed. Sentiment is weak. Expectations are low.

That’s usually where leadership starts.

$UNH and $OSCR in particular look interesting to me.

$UNH is a cash-flow machine with scale, data, and diversification across insurance and care delivery. It’s not flashy, but it compounds.

$OSCR is higher beta, but it’s building a tech-driven insurance model in a massive market. If execution continues and margins improve, the upside could surprise people.

Both are positioned well long term.

If capital rotates out of crowded trades and into overlooked sectors, healthcare could have a big year.

Sometimes the best opportunities aren’t the loudest ones.

[The Valuation Analyst @ValuationEdge_]

$UNH trades at 11x EV/EBITDA

Revenues continue to compound

Cash flow is strong